OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences.
Details for the presentations are as follows:
Event: Healthcare Company Showcase hosted by Alliance Global Partners
Date and Time: Tuesday, May 21, 2024, at 3:20 PM ET
Webcast Link
Event: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Date and Time: Wednesday, May 22, 2024, at 3:40 PM ET
Webcast Link
Live webcasts of the presentations will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
| Last Trade: | US$0.22 |
| Daily Change: | -0.002 -0.92 |
| Daily Volume: | 358,363 |
| Market Cap: | US$13.710M |
December 12, 2024 December 02, 2024 November 19, 2024 November 15, 2024 October 03, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
